Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial

BACKGROUND: One key pathological finding in giant cell arteritis (GCA) is the presence of interferon-gamma and interleukin (IL)-17 producing T helper (Th) 1 and Th17 cells in affected arteries. There is anecdotal evidence of successful induction and maintenance of remission with the monoclonal anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: Venhoff, Nils, Schmidt, Wolfgang A., Lamprecht, Peter, Tony, Hans-Peter, App, Christine, Sieder, Christian, Legeler, Carolin, Jentzsch, Claudia, Thiel, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369438/
https://www.ncbi.nlm.nih.gov/pubmed/34404463
http://dx.doi.org/10.1186/s13063-021-05520-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369438/
https://www.ncbi.nlm.nih.gov/pubmed/34404463
http://dx.doi.org/10.1186/s13063-021-05520-1

Ejemplares similares